Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

A roundup of health news includes Mexico's first screwworm myiasis case, rising measles cases in Texas, the launch of a new ...

Regeneron’s COVID-19 antibody cocktail ... and has already demonstrated the benefits of dexamethasone as a treatment for COVID-19, showing the cheap steroid cut recovery times and reduced ...

People who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron's antibody therapy REGN-COV, according to new data from the UK RECOVERY trial.

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Regeneron Pharmaceuticals ... or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

PARIS, France I April 15, 2025 I Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial. Novartis ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...